

Can't find Insulin Aspart (NovoLog, Fiasp) at your pharmacy? Here are proven tools and tips to locate it in stock near you in 2026.
You need your mealtime insulin. Your pharmacy doesn't have it. And every hour that passes without a plan feels more stressful than the last.
If you're having trouble finding Insulin Aspart — whether it's NovoLog, Fiasp, or a biosimilar version — you're dealing with a problem that thousands of patients across the country are facing right now. With Novo Nordisk discontinuing several NovoLog product forms at the end of 2025 and biosimilar supply still ramping up, finding Insulin Aspart in stock takes a bit more effort than it used to.
The good news? There are real, practical strategies that work. Here are the best ways to track down your medication.
This is the fastest way to find Insulin Aspart near you.
Medfinder is a free tool that shows you which pharmacies in your area currently have your medication in stock. Instead of calling pharmacy after pharmacy, you can search once and see your options.
Here's how to use it:
Medfinder is especially useful during shortages because it's updated regularly and covers independent pharmacies — not just the big chains.
When a drug is in short supply, the big chain pharmacies (CVS, Walgreens, Rite Aid) are usually the first to run out. They serve the most patients, so their stock gets depleted quickly.
Independent pharmacies — the locally owned shops — often have stock when the chains don't. Here's why:
Don't overlook specialty pharmacies either. Some focus specifically on diabetes medications and may have better access to supply.
Pro tip: When you call, ask specifically about all available forms — vials, FlexTouch pens, and biosimilars (Kirsty, Merilog). You might find one form in stock even when another is unavailable.
Pharmacy stock levels fluctuate throughout the week. Deliveries from wholesalers typically arrive on specific days, and stock gets depleted as the week progresses.
Some strategies that help:
If none of the above works, you have more options:
Kirsty (insulin aspart-xjhz) is an interchangeable biosimilar to NovoLog. That means your pharmacist can substitute it for NovoLog without calling your doctor for a new prescription. Merilog (insulin aspart-szjj) is another biosimilar option, though your doctor may need to write a new prescription for it.
If Insulin Aspart isn't available in any form, talk to your doctor about switching to another rapid-acting insulin. Insulin Lispro (Humalog, Admelog, Lyumjev) and Insulin Glulisine (Apidra) work in a similar way and may be easier to find. Read our full breakdown of alternatives to Insulin Aspart.
Novo Nordisk's NovoCare program (1-888-668-6444 or novocare.com) can help you locate supply, access savings cards, and connect with patient assistance programs if cost is a barrier.
Your insurance plan may have a shortage exception process that allows you to fill your prescription at a different pharmacy or switch to an alternative medication without prior authorization delays. Call the number on the back of your insurance card and explain the situation.
Shortages can come and go. Here are a few habits that help you stay ahead:
Finding Insulin Aspart during a shortage takes more effort, but it's not impossible. The key is to be proactive: use tools like Medfinder, explore independent pharmacies, ask about biosimilars, and stay in touch with your healthcare team.
Nobody should have to go without their insulin. If you're struggling, don't wait — start searching now and reach out for help.
Want to understand why this shortage is happening? Read our explainer: Why is Insulin Aspart so hard to find? Or check out our guide to saving money on Insulin Aspart in 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.